CD19 and neoplasm: For example, electroporation-loading of MYC oncogene-targeting sgRNA/Cas9 plasmids into CD19-chimeric-antigen receptor-modified HEK293T cells produced EVs results in a higher distribution in CD19 positive tumour tissues and more effective MYC genome editing than that of plain EVs [19].